Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created

pharmafile | November 20, 2019 | News story | Manufacturing and Production, Research and Development Eli Lilly, US, pharma 

Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center campus in Indianapolis, the company announced, in a move to step up to increasing demand for its medicines.

According to the company, this investment will create around 100 new “highly skilled” positions at the site, as well as deliver enhancements to its insulin-producing manufacturing facilities, expand its capability to further develop its diabetes portfolio, and provide initial capital investments for products it aims to develop in the future.

The investment is the latest in $5 billion that Lilly has committed to its US operations since 2012. Of this figure, its Indiana facilities have been the primary beneficiary, while just under $2 billion of the sum has gone directly into the manufacture of its diabetes medications.

“These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017,” commented David A Ricks, Lilly’s Chairman and Chief Executive Officer. “With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state’s economy and drive future investment – adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace.”

Myles O’Neill, Senior Vice President and President of Manufacturing Operations at the company, echoed these sentiments, remarking: “These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations. All of these projects support Lilly’s investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s …

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for …

Latest content